Compare ProShares UltraShort Bloomberg Natural Gas ETF (KOLD) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ProShares UltraShort Bloomberg Natural Gas ETF vs ResMed Inc. — how do they compare? ProShares UltraShort Bloomberg Natural Gas ETF trades at $27.56, while ResMed Inc. trades at $196 (market cap $28.81B). The key difference: ResMed Inc. pays a 1.21% dividend while ProShares UltraShort Bloomberg Natural Gas ETF pays none, and ProShares UltraShort Bloomberg Natural Gas ETF is trading nearer its 52-week high, ResMed Inc. nearer its low. Which is the better fit depends on your goals.
| KOLD | RMD | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $49.39 | $293.73 |
52-Week Low | $13.58 | $182.82 |
Market Cap | — | $28.81B |
Enterprise Value | — | $27.99B |
Dividend Yield | — | 1.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KOLD trades at $28.25, up 4.01% today, with a bullish technical signal from moving averages and strong trend strength indicated by ADX. Recent news highlights natural gas market volatility driven by weather forecasts and storage reports, with the ETF positioned as a tactical trading tool amid price swings around $3/MMBtu (Seeking Alpha, 2026-06-08).
The outlook remains tied to natural gas price movements, with opportunities for short-term gains from volatility but risks from weather-dependent demand shifts and production levels. Investors face commodity price exposure and leverage risks inherent in inverse ETFs.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ProShares UltraShort Bloomberg Natural Gas ETF
KOLD is an inverse leveraged ETF that seeks to provide two times (2x) the inverse daily performance of the Bloomberg Natural Gas Subindex. It is designed for investors looking to profit from falling natural gas prices.
Read more on KOLD →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
